PMID- 9211625
OWN - NLM
STAT- MEDLINE
DCOM- 19970909
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 86
IP  - 5
DP  - 1997 Jun 1
TI  - Enoxaparin, a low-molecular-weight heparin suppresses prothrombin activation more 
      effectively than unfractionated heparin in patients treated for venous 
      thromboembolism.
PG  - 349-54
AB  - Although unfractionated heparin (UFH) is standard therapy for venous 
      thromboembolism, there is a clinical failure rate of up to 10%. Newer treatment 
      strategies include low-molecular-weight heparins (LMWH). As part of an 
      international study comparing the efficacy and safety of enoxaparin, a LMWH 
      versus UFH in patients with venous thromboembolism, we studied the effects of 
      enoxaparin and UFH on the plasma concentrations of two activation peptides, 
      fragment 1 + 2 (F1 + 2), and thrombin-antithrombin III (TAT) complexes. We 
      hypothesized that enoxaparin would be more effective in suppressing activation of 
      coagulation. Intravenous heparin was given by bolus injection followed by 
      infusion. There were 2 enoxaparin treatment groups (1 mg/kg s.c., bid and 1.5 
      mg/kg s.c. daily). Plasma samples were obtained from 11 patients in the 
      enoxaparin group and 6 patients in the heparin group prior to and at 6 hour 
      intervals after initiating therapy. Clinical characteristics of the enoxaparin 
      and UFH patient groups were similar. TAT concentrations were not statistically 
      different between groups at any treatment interval. However, plasma F1 + 2 
      concentrations differed significantly (p < 0.05); concentrations in the 
      enoxaparin group were consistently lower over time than in the UFH group. These 
      results suggest that this LMWH is more effective in suppressing ongoing 
      thrombosis in vivo than UFH in patients with venous thrombosis.
FAU - Grosset, A B
AU  - Grosset AB
AD  - Department of Medicine, University of Utah Health Sciences Center, Salt Lake City 
      84132, USA.
FAU - Spiro, T E
AU  - Spiro TE
FAU - Beynon, J
AU  - Beynon J
FAU - Rodgers, G M
AU  - Rodgers GM
LA  - eng
GR  - M01-RR-00064/RR/NCRR NIH HHS/United States
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 0 (Peptide Fragments)
RN  - 0 (antithrombin III-protease complex)
RN  - 0 (prothrombin fragment 1.2)
RN  - 9000-94-6 (Antithrombin III)
RN  - 9001-26-7 (Prothrombin)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.- (Peptide Hydrolases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Antithrombin III/metabolism
MH  - Enoxaparin/administration & dosage/*therapeutic use
MH  - Female
MH  - Heparin/administration & dosage/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptide Fragments/metabolism
MH  - Peptide Hydrolases/metabolism
MH  - Prothrombin/*metabolism
MH  - Safety
MH  - Thromboembolism/*blood/*drug therapy
EDAT- 1997/06/01 00:00
MHDA- 1997/06/01 00:01
CRDT- 1997/06/01 00:00
PHST- 1997/06/01 00:00 [pubmed]
PHST- 1997/06/01 00:01 [medline]
PHST- 1997/06/01 00:00 [entrez]
AID - S0049-3848(97)00079-0 [pii]
AID - 10.1016/s0049-3848(97)00079-0 [doi]
PST - ppublish
SO  - Thromb Res. 1997 Jun 1;86(5):349-54. doi: 10.1016/s0049-3848(97)00079-0.